Rabe Etienne, Cioni Dania, Baglietto Laura, Fornili Marco, Gabelloni Michela, Neri Emanuele
Academic Radiology, Master in Oncologic Imaging, Department of Translational Research, University of Pisa, Pisa 56126, Italy.
Department of Clinical and Experimental Medicine, University of Pisa, Pisa 56126, Italy.
World J Hepatol. 2022 Jan 27;14(1):244-259. doi: 10.4254/wjh.v14.i1.244.
Artificial intelligence in radiology has the potential to assist with the diagnosis, prognostication and therapeutic response prediction of various cancers. A few studies have reported that texture analysis can be helpful in predicting the response to chemotherapy for colorectal liver metastases, however, the results have varied. Necrotic metastases were not clearly excluded in these studies and in most studies the full range of texture analysis features were not evaluated. This study was designed to determine if the computed tomography (CT) texture analysis results of non-necrotic colorectal liver metastases differ from previous reports. A larger range of texture features were also evaluated to identify potential new biomarkers.
To identify potential new imaging biomarkers with CT texture analysis which can predict the response to first-line cytotoxic chemotherapy in non-necrotic colorectal liver metastases (CRLMs).
Patients who presented with CRLMs from 2012 to 2020 were retrospectively selected on the institutional radiology information system of our private radiology practice. The inclusion criteria were non-necrotic CRLMs with a minimum size of 10 mm (diagnosed on archived 1.25 mm portal venous phase CT scans) which were treated with standard first-line cytotoxic chemotherapy (FOLFOX, FOLFIRI, FOLFOXIRI, CAPE-OX, CAPE-IRI or capecitabine). The final study cohort consisted of 29 patients. The treatment response of the CRLMs was classified according to the RECIST 1.1 criteria. By means of CT texture analysis, various first and second order texture features were extracted from a single non-necrotic target CRLM in each responding and non-responding patient. Associations between features and response to chemotherapy were assessed by logistic regression models. The prognostic accuracy of selected features was evaluated by using the area under the curve.
There were 15 responders (partial response) and 14 non-responders (7 stable and 7 with progressive disease). The responders presented with a higher number of CRLMs ( = 0.05). In univariable analysis, eight texture features of the responding CRLMs were associated with treatment response, but due to strong correlations among some of the features, only two features, namely minimum histogram gradient intensity and long run low grey level emphasis, were included in the multiple analysis. The area under the receiver operating characteristic curve of the multiple model was 0.80 (95%CI: 0.64 to 0.96), with a sensitivity of 0.73 (95%CI: 0.48 to 0.89) and a specificity of 0.79 (95%CI: 0.52 to 0.92).
Eight first and second order texture features, but particularly minimum histogram gradient intensity and long run low grey level emphasis are significantly correlated with treatment response in non-necrotic CRLMs.
放射学中的人工智能有潜力辅助各种癌症的诊断、预后评估及治疗反应预测。一些研究报告称,纹理分析有助于预测结直肠癌肝转移对化疗的反应,然而,结果各不相同。这些研究未明确排除坏死性转移灶,且在大多数研究中未评估完整范围的纹理分析特征。本研究旨在确定非坏死性结直肠癌肝转移的计算机断层扫描(CT)纹理分析结果是否与先前报告不同。还评估了更广泛的纹理特征以识别潜在的新生物标志物。
通过CT纹理分析识别潜在的新影像生物标志物,以预测非坏死性结直肠癌肝转移(CRLMs)对一线细胞毒性化疗的反应。
在我们私人放射科的机构放射学信息系统中回顾性选择2012年至2020年出现CRLMs的患者。纳入标准为最小尺寸为10mm的非坏死性CRLMs(根据存档的1.25mm门静脉期CT扫描诊断),接受标准一线细胞毒性化疗(FOLFOX、FOLFIRI、FOLFOXIRI、CAPE - OX、CAPE - IRI或卡培他滨)。最终研究队列包括29名患者。CRLMs的治疗反应根据RECIST 1.1标准分类。通过CT纹理分析,从每个有反应和无反应患者的单个非坏死性目标CRLMs中提取各种一阶和二阶纹理特征。通过逻辑回归模型评估特征与化疗反应之间的关联。使用曲线下面积评估所选特征的预后准确性。
有15名有反应者(部分缓解)和14名无反应者(7名病情稳定,7名病情进展)。有反应者的CRLMs数量更多(P = 0.05)。在单变量分析中,有反应的CRLMs的八个纹理特征与治疗反应相关,但由于某些特征之间的强相关性,多变量分析中仅纳入了两个特征,即最小直方图梯度强度和长游程低灰度级强调。多模型的受试者操作特征曲线下面积为0.80(95%CI:0.64至0.96),敏感性为0.73(95%CI:0.48至0.89),特异性为0.79(95%CI:0.52至0.92)。
八个一阶和二阶纹理特征,特别是最小直方图梯度强度和长游程低灰度级强调与非坏死性CRLMs的治疗反应显著相关。